Foghorn Therapeutics Inc logo

FHTX

Foghorn Therapeutics Inc

$15.47

Earnings Summary

Revenue
$3.92Mn
Net Profits
$-26.91Mn
Net Profit Margins
-686.58%

Highlights

Revenue:

Foghorn Therapeutics Inc’s revenue jumped 1270.63% since last year same period to $3.92Mn in the Q1 2022. On a quarterly growth basis, Foghorn Therapeutics Inc has generated 748.28% jump in its revenue since last 3-months.

Net Profits:

Foghorn Therapeutics Inc’s net profit fell -17.09% since last year same period to $-26.91Mn in the Q1 2022. On a quarterly growth basis, Foghorn Therapeutics Inc has generated -137.34% fall in its net profits since last 3-months.

Net Profit Margins:

Foghorn Therapeutics Inc’s net profit margin jumped 91.46% since last year same period to -686.58% in the Q1 2022. On a quarterly growth basis, Foghorn Therapeutics Inc has generated 94.24% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Foghorn Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.52
EPS Estimate Current Year
-0.52

Highlights

EPS Estimate Current Quarter:

Foghorn Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.52 - a -6.12% fall from last quarter’s estimates.

EPS Estimate Current Year:

Foghorn Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.52.

Key Ratios

Key ratios of the Foghorn Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.65
Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-1.44
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Foghorn Therapeutics Inc’s earning per share (EPS) fell -4.84% since last year same period to -0.65 in the Q1 2022. This indicates that the Foghorn Therapeutics Inc has generated -4.84% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Foghorn Therapeutics Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Foghorn Therapeutics Inc’s return on equity (ROE) stands at -1.44.

Dividend Per Share (DPS):

Foghorn Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.52
-0.65
-25%

Company Information

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The Company's proprietary Gene Traffic Control® platform gives it an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system.

Organisation
Foghorn Therapeutics Inc
Employees
95
Industry
Health Technology